Emerging Maintenance Strategies in Advanced/Metastatic Disease: Insights on Combination Therapies and Overcoming PARP Inhibitor Resistance

Panelists discuss PARP inhibitor resistance in ovarian cancer and explore strategies to overcome this challenge, including findings from the PRESERVE-004 trial evaluating gotistobart plus pembrolizumab, along with other potential treatment options. Additionally, they review insights from the SOPRANO trial regarding the management of oligometastases or oligoprogression in ovarian cancer.

EP: 1.Biomarker Testing in Advanced Ovarian Cancer

EP: 2.Role of Genomic Instability Scores in Treatment Selection

EP: 3.Brief Overview of Frontline Maintenance Therapy for Advanced Ovarian Cancer

EP: 4.Optimizing PARP Inhibitor Duration

EP: 5.Overview of PRIMA - Niraparib 1L Maintenance

Now Viewing

EP: 6.Emerging Maintenance Strategies in Advanced/Metastatic Disease: Insights on Combination Therapies and Overcoming PARP Inhibitor Resistance

Video content above is prompted by the following:

1. Dr Chan to ask Dr Herzog: Please comment on PARP inhibitor resistance. Are there promising strategies to overcome this challenge?

• PRESERVE-004: gotistobart plus pembrolizumab (Barlin JN, et al. ESMO 2024. LBA32)
• Others?

Dr Herzog to ask Dr Chan: What insights can be drawn from the SOPRANO trial findings regarding the management of oligometastases or oligoprogression in ovarian cancer? (Banerjee S, et al. ESMO 2024. Abs 798TiP)

Related Videos